NICE, the body that makes reimbursement recommendations for England’s National Health Service, has given the thumbs down to Pfizer Inc.’s PARP inhibitor Talzenna (talazoparib) for the treatment of certain types of advanced breast cancer in preliminary guidance on 28 July, saying the drug is not a cost-effective use of NHS resources.
In it draft guidance, NICE cited Talzenna’s lack of overall survival benefit compared with chemotherapy as a main reason the drug could not be recommended for NHS use
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?